Grants per year
Personal profile
Training Experience
| 1996 | Fellowship, Wayne State University |
| 1999 | Internship, Wayne State University |
| 2002 | Residency, University of Chicago Hospitals |
| 2004 | Fellowship, University of Chicago Hospitals |
Education/Academic qualification
MD, Medical Academy, Sofia, Bulgaria
… → 1991
Fingerprint
Dive into the research topics where Roumen Deltchev Balabanov is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Northwestern MS/Neuroimmunology fellowship proposal
National Multiple Sclerosis Society
7/1/21 → 6/30/22
Project: Research project
-
Prot #101MS329: A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching Fro
Quintiles, Inc., Biogen MA Inc.
6/14/19 → 6/14/22
Project: Research project
-
Identifying Immune Cell Surface Markers in Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System
3/22/19 → 3/22/22
Project: Research project
-
Autologous Hematopoietic Stem Cell Transplantation for Stiff-Person Spectrum Disorder: A Clinical Trial
Burt, R. K., Balabanov, R., Han, X., Quigley, K., Arnautovic, I., Helenowski, I., Rose, J. & Siddique, T., Feb 9 2021, In: Neurology. 96, 6, p. e817-e830Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study (Advances in Therapy, (2021), 38, 7, (3724-3742), 10.1007/s12325-021-01722-w)
Perumal, J., Balabanov, R., Su, R., Chang, R., Balcer, L., Galetta, S., Campagnolo, D. I., Avila, R., Lee, L., Rutledge, D. & Fox, R. J., Jul 2021, In: Advances in Therapy. 38, 7, p. 3743-3744 2 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Perumal, J., Balabanov, R., Su, R., Chang, R., Balcer, L., Galetta, S., Campagnolo, D. I., Avila, R., Lee, L., Rutledge, D. & Fox, R. J., Jul 2021, In: Advances in Therapy. 38, 7, p. 3724-3742 19 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers”
Graham, E. L., Clark, J. R., Orban, Z. S., Lim, P. H., Szymanski, A. L., Taylor, C., DiBiase, R. M., Jia, D. T., Balabanov, R., Ho, S. U., Batra, A., Liotta, E. M. & Koralnik, I. J., May 2021, In: Annals of clinical and translational neurology. 8, 5, p. 1073-1085 13 p.Research output: Contribution to journal › Article › peer-review
Open Access21 Scopus citations -
The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP
Burt, R. K., Tappenden, P., Balabanov, R., Han, X., Quigley, K., Snowden, J. A. & Sharrack, B., Mar 22 2021, In: Frontiers in Neurology. 12, 645263.Research output: Contribution to journal › Article › peer-review
Open Access